Andrey V. Khorinko

Statistics

Publications

Citations

114

H-Index

Active since

2013

Affiliations

Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser(Current)

BIOCAD (Russia)

Russian Cancer Research Center NN Blokhin

Moscow City Oncology Hospital №62

Volgograd Regional Clinical Oncology Center

Andrey V. Khorinko is an author at Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser specializing in pharmacology, clinical trial reports, and oncology.

Publications per year

2013–2020

Publications

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013 · 56 citations · Full text

Medicine, Oncology, Pharmacology +9

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

Sergey Alexeev, Andrey V. Khorinko, Guzel Mukhametshina et al. · BMC Cancer · 2020 · 17 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC.

O. V. Filon, Sergey Orlov, Olga Burdaeva et al. · Journal of Clinical Oncology · 2015 · 16 citations

Medicine, Oncology, Pharmacology +10

Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients.

Sergey Orlov, Olga Burdaeva, Marina P. Nechaeva et al. · Journal of Clinical Oncology · 2014 · 14 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients.

E. Ignatova, Olga Burdaeva, Marina P. Nechaeva et al. · Journal of Clinical Oncology · 2014 · 11 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

1–5 of 5